S. Zuniga

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

D. Moro, A. Cervantes, N. Tarazona, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

D. Moro, A. Cervantes, N. Tarazona, 2019 .

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

A. Sadanandam, F. Papaccio, G. Nyamundanda, 2020, ESMO Open.

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

R. Rosell, R. Sirera, C. Camps, 2020, Translational lung cancer research.

Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype

F. Papaccio, D. Moro, G. Nyamundanda, 2019, Annals of Oncology.